ADHD Feels Like It's Everywhere? Researchers See No Upswell
ADHD may seem like it's everywhere at the moment, but researchers found its prevalence hasn't changed much in recent years.
A review by King's College London 's Institute of Psychiatry, Psychology & Neuroscience found that the proportion of people with a medical diagnosis for attention deficit hyperactivity disorder didn't increase meaningfully between 2020 and 2024. The findings published Thursday are based on four studies only, due to the poor quality of most of the others reviewed by the researchers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
27 minutes ago
- Associated Press
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine's label to include treatment for suicidal depression, backed by clinical data from more than 1,000 patients. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
Forbes
27 minutes ago
- Forbes
Late ADHD Diagnoses In Women Are Shaping A New Leadership Model
For many high-achieving women, leadership has meant working twice as hard to prove they belong in the room. But for a growing number, there's another layer to the story, and it was hidden in plain sight for years. Women are being diagnosed with ADHD not in childhood but in midlife, after decades of navigating leadership roles with an invisible challenge. Between 2020 and 2022, the incidence of ADHD diagnoses among women aged 23–29 and 30–49 nearly doubled. This trend highlights the growing awareness that ADHD often presents differently in women and is frequently diagnosed later in life compared to men, as reported by Epic Research. Attention-Deficit/Hyperactivity Disorder has long been seen as a childhood condition, typically associated with hyperactive boys disrupting classrooms. But women—especially those in leadership—often don't fit the mold. They may present as driven, organized and articulate. Behind the scenes, though, many are masking executive dysfunction, working long hours to compensate for distractibility and feeling constant internal overwhelm. 'Women with ADHD tend to display more difficulties with attention compared to men,' states Anne Castley Burdzy, PhD., founder of BeWell Psychology. 'Women in leadership roles might find themselves task-switching more frequently or maybe more easily distracted compared to their male counterparts.' Women are significantly more likely to be diagnosed later in life during career transitions or hormonal changes. For female leaders, that late diagnosis sparks both relief and regret. Once diagnosed, many women experience a seismic shift—not in capability, but in self-compassion. Rather than framing their struggles as personal failings, they begin to reframe them as neurological differences. That lens allows for greater empathy toward themselves and, in many cases, their teams. It also transforms how they lead. 'You are not broken, lazy or unqualified; your brain just works differently, and that's not a flaw, it's a feature,' Summer Jelinek, a keynote speaker and leadership trainer, advises emerging leaders. 'Build systems that work for your brain, not against it.' Jelinek discovered her ADHD during her Ph.D. program, adding to her earlier autism diagnosis. This dual realization, known as AuDHD, provided clarity on her past corporate experiences and leadership challenges. 'That internal tug-of-war confused me and definitely confused my leaders,' she explains. 'I spent a massive amount of energy trying to hide both, constantly managing how I showed up so I didn't seem too intense, too much or too sensitive.' Post-diagnosis, Jelinek wears her neurodivergence on her sleeve, creating a safe space for others; she leads from a place of authenticity rather than performance. She emphasizes the importance of building systems that align with one's unique cognitive patterns. For Pubali Sen, head of ChomChomTech and serving as AI/ML Solutions at Google, the realization of her ADHD at age 31 was a transformative moment. 'My 'aha!' moment was less of a gentle dawn and more of a full-blown fireworks display,' she recounts. This diagnosis provided clarity on her past behaviors and led her to develop structured systems to manage her responsibilities effectively. Sen describes her ADHD as a catalyst for innovation. 'My ADHD brain is like having a super-fast internet connection with about 50 tabs open simultaneously,' she explains. Embracing her neurodivergence, she advocates for inclusive leadership that values diverse cognitive styles. At ChomChomTech, Sen channels her experiences into creating AI-powered tools that support the emotional regulation and imaginative skills of neurodivergent children. Her leadership exemplifies how understanding and embracing one's cognitive profile leads to more effective and empathetic leadership. Sandra Bean, founder of St. Pete Girl Boss, was diagnosed at 40, which led to a transformation in her leadership approach from self-criticism to self-compassion. 'I realized it wasn't that I wasn't trying hard enough,' she reflects. 'I needed extra support.' From this insight, she implements supportive systems such as time blocking. Bean's ADHD has enhanced her networking and negotiation skills. However, she acknowledges challenges such as rejection sensitivity and time blindness, which she addresses through strategies like body doubling. She has another person present while working on a task, either in person or virtually, to stay focused and motivated. This person doesn't actively help with the task itself; they are there to act as an accountability partner. Bean advocates for leadership that values cognitive flexibility. 'We don't do things the 'normal' way; we do them the necessary way,' she asserts, emphasizing the importance of creating spaces where diverse minds can thrive. Leadership doesn't require perfect focus or linear thinking. By embracing ADHD as a strength, these women are creating new models for what effective, empathetic leadership can look like. The future of leadership is not quieter or neater. It is more human and raw. Key characteristics of this emerging ADHD-informed leadership model include: Neuro-inclusive workplaces are the future of organizations; it's about redesigning meetings to reduce cognitive overload and offering more flexible workflows while being transparent about how neurodivergent leaders' brains function. The more these leaders share their stories, the more they're paving the way for others, especially younger employees who may be struggling silently. The diagnosis isn't a weakness. For many, it's a key to unlocking their full leadership potential. 'Specific accommodations for women with ADHD include providing clear expectations, allowing ample time for tasks with effective prompts and breaking larger tasks into smaller, manageable parts,' Dr. Castley Burdzy concludes. 'Creating a workplace environment that is healthy and supportive gives leaders a space to advocate and implement strategies that they find helpful.'
Yahoo
an hour ago
- Yahoo
Women less likely to get care for potentially fatal heart condition
Women are less likely than men to be given treatment for a potentially fatal heart condition, according to a new analysis. Researchers in the UK found women are 11% less likely to be referred to a hospital specialist after a diagnosis of the heart valve disease aortic stenosis. Academics said the findings show 'inequities in management and care of this common and serious condition' after they also found differences in care among south Asian and black patients as well as those from poorer backgrounds. Aortic stenosis, a narrowing of the aortic valve or the area immediately around it, leads to obstruction of the blood flow from the heart, which leads to symptoms including dizziness, fatigue, chest pain and breathlessness. The condition is more common in elderly people. It is not possible to reverse but treatments can include a transcatheter aortic valve implantation (TAVI) or valve replacement surgery. If left untreated it can lead to serious complications, including heart failure, heart rhythm abnormalities, and death. The analysis suggests some people are less likely to receive this treatment. Experts from England's University of Leicester examined GP data on 155,000 people diagnosed with aortic stenosis between 2000 and 2022 in England. Presenting their findings to the British Cardiovascular Society conference in Manchester, experts said as well as women being less likely to be referred for hospital care, they are 39% less likely to have a procedure to replace their aortic valve. Researchers also found people living in poorer neighbourhoods are 7% less likely to be referred for hospital care after a diagnosis compared to people from wealthier neighbourhoods. Meanwhile, black patients are 48% less likely to undergo a procedure to replace their aortic valve compared to white patients. South Asian patients are 27% less likely to undergo a procedure compared to their white counterparts, according to the study, which was funded by the National Institute for Health and Care Research (NIHR) and supported by NIHR Leicester Biomedical Research Centre. Dr Anvesha Singh, associate professor at the University of Leicester and consultant cardiologist, who was involved in the research, said: 'Previous studies have shown lower rates of valve replacement in women, and clinicians had assumed that women were less likely to be diagnosed with aortic stenosis. 'This analysis using large, real-world data clearly shows that this is not the case, giving us the clearest picture yet of what is happening in day-to-day clinical practice. 'Our study highlights potential inequities in management and care of this common and serious condition. More research is needed to understand the reasons for this and the true prevalence of aortic stenosis in different groups.'
